

December 6, 2022

Kidswell Bio Corporation

Code: 4584 (TSE Mothers)

Masaharu Tani, President & CEO

Announcement of request for convocation of extraordinary meeting of shareholders (excerpt from Japanese version)

Tokyo, December 6, 2022 – Kidswell Bio Corporation (KWB) announces to have received a request for the convocation of an extraordinary meeting of shareholders under the provision of Article 297, Paragraph 1 of the Companies Act on Dec. 6, 2022.

1. Outline of the claimants

Shareholders who have more than 3 percent of the voting rights of the Company's total shares for the past six months.

2. The date of which the claim was made

December 5, 2022

3. Details of the claim

(1) Proposal by a Shareholder

Election of One (1) Director (outside)

Name of the candidate: Mr. Koichi Otomo, former President & CEO of Advanced Cell Technology and Engineering Ltd. (ACTE)

(2) Reasons for convocation

As a solution for improvement of stock prices, Mr. Otomo, who has a track record of media exposure as former president & CEO of ACTE and is also the largest individual shareholder, is expected to be able to build a relationship and a trust with shareholders and improve corporate value.

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com